BRVE · Forms 3, 4, 5
Insider trades at Braveheart Bio, Inc.
10 insiders bought $159M of Braveheart Bio, Inc. stock on the open market in the last 90 days.
Every Form 3, 4 and 5 filed for Braveheart Bio, Inc. (BRVE) with the SEC, newest first: who traded, their role, buy or sell, shares, price and value.
Insider trades in the last 90 days
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Vineeta Agarwala | Director | Became an insider (Form 3) | Form 3 | ||||
| AH Bio Fund IV, L.P. | 10% owner | Conversion | 9,132,420 | Form 4 | |||
| AH Bio Fund IV, L.P. | 10% owner | Buy | 1,100,000 | $18.00 | $19.8M | Form 4 | |
| Erez Chimovits | Director | Conversion | 9,132,420 | Form 4 | |||
| Erez Chimovits | Director | Buy | 1,666,667 | $18.00 | $30M | Form 4 | |
| Erez Chimovits | Director | Buy | 273,333 | $18.00 | $4.9M | Form 4 | |
| ORBIMED ADVISORS LLC | Director | Conversion | 9,132,420 | Form 4 | |||
| ORBIMED ADVISORS LLC | Director | Buy | 1,666,667 | $18.00 | $30M | Form 4 | |
| ORBIMED ADVISORS LLC | Director | Buy | 273,333 | $18.00 | $4.9M | Form 4 | |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% owner | Conversion | 7,420,091 | Form 4 | |||
| Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% owner | Conversion | 9,132,420 | Form 4 | |||
| Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% owner | Conversion | 7,990,867 | Form 4 | |||
| Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% owner | Buy | 1,920,000 | $18.00 | $34.6M | Form 4 | |
| Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% owner | Buy | 1,680,000 | $18.00 | $30.2M | Form 4 | |
| James Paul Rickey | Chief Financial Officer | Buy | 27,777 | $18.00 | $500K | Form 4 | |
| Tim Lohoff | Director | Options or other derivatives | Form 4 | ||||
| Erez Chimovits | Director | Options or other derivatives | Form 4 | ||||
| Christopher Viehbacher | Director | Buy | 83,333 | $18.00 | $1.5M | Form 4 | |
| David I Malek | Director | Buy | 4,166 | $18.00 | $75K | Form 4 | |
| Michele A. Anderson | Chief Development Officer | Buy | 1,111 | $18.00 | $20K | Form 4 | |
| Travis Murdoch | CEO and President | Buy | 83,333 | $18.00 | $1.5M | Form 4 | |
| Jasper Bos | Director | Options or other derivatives | Form 4 | ||||
| David Charles Lubner | Director | Buy | 55,555 | $18.00 | $1M | Form 4 | |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% owner | Became an insider (Form 3) | Form 3 | ||||
| ORBIMED ADVISORS LLC | Director | Became an insider (Form 3) | Form 3 | ||||
| AH Bio Fund IV, L.P. | 10% owner | Became an insider (Form 3) | Form 3 | ||||
| Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% owner | Became an insider (Form 3) | Form 3 | ||||
| James Paul Rickey | Chief Financial Officer | Became an insider (Form 3) | Form 3 | ||||
| Christopher Viehbacher | Director | Became an insider (Form 3) | Form 3 | ||||
| Jasper Bos | Director | Became an insider (Form 3) | Form 3 | ||||
| David Charles Lubner | Director | Became an insider (Form 3) | Form 3 | ||||
| Michele A. Anderson | Chief Development Officer | Became an insider (Form 3) | Form 3 | ||||
| Erez Chimovits | Director | Became an insider (Form 3) | Form 3 | ||||
| Travis Murdoch | CEO and President | Became an insider (Form 3) | Form 3 | ||||
| Tim Lohoff | Director | Became an insider (Form 3) | Form 3 | ||||
| David I Malek | Director | Became an insider (Form 3) | Form 3 | ||||
| Jason V Coloma | Director | Became an insider (Form 3) | Form 3 |
Buy and Sell are open-market purchases and sales (transaction codes P and S), the trades investors watch. Awards, option exercises, tax withholding and gifts are reported too but are not market trades.